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efforts aimed at protecting the natural habitat
of the orangutan. Galdikas was instrumental
in establishing the largest national park in
Borneo, and she is involved with numerous
conservation efforts in Indonesia. She has also
been involved with the maintenance ofa care
center for orphaned orangutans and educa-
tional programs for children.
In the late 1950s, Schaller conducted the
first scientific study of the mountain gorilla,
and his book, The Mountain Gorilla, led to
the establishment of the Virungas National
Park in Rwanda. He has also studied tigers,
lions, snow leopards, and pandas, and his
books are known by field biologists around
the world. As director of science for the
Wildlife Conservation Society, Schaller has
been a leading champion of conservation
practices, and his efforts have led to the estab-
lishment of national parks in Brazil, East
Africa, Mongolia, China, Tibet, and the
United States.
Fake DNA
The outlines of chromosome function have
been clear for decades, but a new develop-
ment-the creation of the first artificial
human chromosome-gives scientists the
tools to fill in the details. Reported by
researchers at Cleveland's Case Western
Reserve University School ofMedicine in the
April 1997 issue of Nature Genetics, the new
chromosome should allow scientists to study
gene expression and evolution, and will
potentially improve gene therapy.
The finding also
provides a model for
studying environmental
health, says Huntington
F. Willard, a genetics
professor and senior
author on the study. For
example, researchers can
test how environmental
agents cause chromo-
somes to malfunction
during cell division and
how toxins cause muta-
genesis. Being able to
work with an artifi-
cial human chromosome
brings an experimental
dimension to the Human
Genome Project, says
Willard, whose research
has received funding
from that project for
several years.
Artificial chromosomes could correct
some defects in approaches to gene therapy as
well, the authors contend. Current methods
of gene therapy are hampered by unpre-
dictable gene expression and vector short-
comings. For example, viral vectors can foster
immune reactions, cause cell toxicity, and
transfer only small amounts ofgenetic mater-
ial. Available nonviral vectors do not segre-
gate properly during repeated cell divisions.
"We decided the perfect vector would
resemble a normal human chromosome,"
says John J. Harrington, the study's lead
author and vice president of Athersys, a
Cleveland, Ohio-based company that hopes
to develop the new technology. "A micro ver-
sion small enough to be manipulated and
delivered to cells is the optimal way to go."
Harrington looks toward a future where
physicians can use ready-made chromosomes
to treat a variety ofgenetic diseases.
But such applications are years away from
use because of technical challenges, says Uta
Francke, a genetics professor at the Stanford
University School ofMedicine and a member
of a National Institutes of Health Panel to
Assess the NIH Investment in Research on
Gene Therapy, whose 1995 report called for
better approaches to gene therapy. Still,
Francke said of the new chromosomes, "The
applications for biological research are very
great.
To create the artificial chromosome, Case
Western Reserve researchers pared its struc-
ture down to three essential components:
centromeres, which guide chromosomes dur-
ing cell division, telomeres, repeating DNA
sequences that protect the ends of chromo-
somes and allow replication, and origins of
replication, the sequences where DNA copy-
ing is begin. The scientists cloned
Small wonder. The synthetic human
microchromosome (beneath the arrow) cre-
ated by investigators at Case Western
Reserve University is surrounded by native
human chromosomes. Fluorescent dyes
cause chromosome material to appear blue
while the centromeres appear green.
centromere sequences
consisting of repeats
ofalpha satellite DNA,
huge arrays of a
repeating 171 base-
pair unit. Previous
researchers had been
unable to clone these
large sequences, and
had depended primar-
ily on chopping up
existing chromosomes
rather than creating
new ones. The team
then added these
centromere sequences,
telomere sequences,
and genomic DNA
digested by enzymes to
cultures of human sar-
coma cells.
Cells absorbed the
genetic material, assisted by positively
charged lipids known to aid in DNA uptake.
DNA-repair machinery within the cells
apparently formed the material into chromo-
somes in three ways. Two involved hitching
the DNA to existing chromosomes, which
could disrupt genes. But other cells produced
novel chromosomes that resembled naturally
occurring ones but were 5-10 times smaller.
These microchromosomes replicated normal-
ly through six months of mitotic cell divi-
sion-about 240 generations.
Ethicists expressed optimism that
microchromosomes might overcome some
disadvantages of gene-therapy vectors, but
cautioned that many of the same ethical
questions remain. What are the risks of can-
cer and other side effects? Should adults make
such treatment decisions for children? Should
new genes be added to germ cells? In addi-
tion, questions arise about whether artificial
chromosomes could be used to enhance traits
such as intelligence, and how to address this
possibility, says Michael H. Shapiro of the
University of Southern California Law
School in Los Angeles. "There are some very
serious issues to be discussed," he says.
The Case Western Reserve team built on
more than a decade of Willard's work, and
on previous studies of yeast genetics. Yeast
artificial chromosomes were developed in the
early 1980s, and their use has offered insight
into gene mapping, function, and identifica-
tion. But larger, more complex human chro-
mosomes had defied creation until now.
A first step in refining the discovery is
ensuring that microchromosomes, not other
genetic variants, are formed during the
process, and that genes express reliably.
Currently, the researchers are building
microchromosomes in solution and inserting
them into cells in culture to streamline the
process. They're planning to inject
microchromosomes into mice within the next
six months.
The diseases likely to be attacked first
with artificial human chromosomes are blood
disorders, such as sickle cell anemia. Blood
cells are easily removed from the body and
reinserted after adding genetic material.
Treating other genetic disorders, such as cys-
tic fibrosis, awaits development ofnew meth-
ods for introducing microchromosomes into
the body.
A Known Human Carcinogen
A working group ofthe International Agency
for Research on Cancer (IARC), located in
Lyon, France, has stated that 2,3,7,8-tetra-
chlorodibenzo-p-dioxin (TCDD), the most
toxic form ofdioxin, is a known human car-
cinogen. Since 1987, the IARC has classified
TCDD as a group B2, or "probable human,"
carcinogen.
George Lucier, chairman of the IARC
dioxin working group, which released its
reclassification of TCDD on 11 February
1997, said three lines of evidence were taken
into account: animal studies, human epi-
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